Hospital Ruber Internacional

Madrid 28036

6 studies enrolling now · 29 studies all time

What they study most

Advanced Cancer, Advanced Solid Tumor, Adult, Advanced Solid Tumors, Breast Cancer, Breast Cancer, Breast Neoplasms, Breast Neoplasms, Cervical Cancer, Chemotherapy-induced Peripheral Neuropathy, Cholangiocarcinoma, Colorectal Cancer, Cutaneous Melanoma, Dravet Syndrome

Studies at this site

• A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy — Recruiting now
• A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome — Recruiting now
• LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC — Recruiting now
• A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy — Recruiting now
• A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s) — Recruiting now
• GEN1047 for Solid Tumors - First in Human (FIH) Trial — Stopped early
• A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer — Running, not enrolling
• An Open-label Study of XEN1101 in Epilepsy — Enrolling by invitation
• A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures — Completed
• Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD — Running, not enrolling
• Compassionate Use for BIA 28-6156 in Patients With Parkinson's Disease (PD) Who Have a Pathogenic Variant in the GBA1 Gene (GBA-PD) and Completed the ACTIVATE Study — Available (expanded access)
• Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy — Completed
• A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer — Running, not enrolling
• Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) — Running, not enrolling
• A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease — Completed
• Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] — Running, not enrolling
• A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer — Completed
• MGC018 With or Without MGA012 in Advanced Solid Tumors — Stopped early
• MGD019 DART® Protein in Unresectable/Metastatic Cancer — Completed
• Honeycomb: Evaluation of Radiprodil in Children with GRIN-related Disorder — Running, not enrolling
• A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy — Running, not enrolling
• Efficacy and Safety of ATX01 in Adult Patients With CIPN (Chemotherapy-induced Peripheral Neuropathy) — Running, not enrolling
• Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures — Completed
• A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100) — Completed
• Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer — Stopped early
• A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms — Completed
• Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer — Stopped early
• A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies — Completed
• A Study to Assess the Safety and Efficacy of the of the Gastric-retentive AP-CD/LD in Advanced Parkinson's Patients — Status unconfirmed